Literature DB >> 18645048

Inappropriate left ventricular mass in patients with primary aldosteronism.

Maria Lorenza Muiesan1, Massimo Salvetti, Anna Paini, Claudia Agabiti-Rosei, Cristina Monteduro, Gloria Galbassini, Eugenia Belotti, Carlo Aggiusti, Damiano Rizzoni, Maurizio Castellano, Enrico Agabiti-Rosei.   

Abstract

Assessment of appropriateness of left ventricular mass (LVM) for a given workload may better stratify hypertensive patients. Inappropriate LVM may reflect the interaction of genetic and neurohumoral factors other than blood pressure playing a significant role in myocardial growth. Primary aldosteronism (PA) represents a clinical model useful in assessing the effect of aldosterone increase on LVM. The aim of this study was to evaluate the inappropriateness of LVM in patients with PA. In 125 patients with PA (54 females; adrenal hyperplasia in 73 and adenoma in 52 patients) and in 125 age-, sex-, and blood pressure-matched, essential hypertensive patients, echocardiography was performed. The appropriateness of LVM was calculated by the ratio of observed LVM to the predicted value using a reference equation. In all of the subjects plasma renin activity and aldosterone, as well as clinic and 24-hour blood pressure, were measured. The prevalence of inappropriate LVM was greater in patients with traditionally defined left ventricular hypertrophy (70% and 44%, respectively; P=0.02) but also in patients without left ventricular hypertrophy (17% and 9%, respectively; P=0.085). In PA patients, a correlation was observed between the ratio of observed:predicted LVM and the ratio of aldosterone:plasma renin activity levels (r=0.29; P=0.003) or the postinfusion aldosterone concentration (r=0.44; P=0.004; n=42). In conclusion, in patients with PA, the prevalence of inappropriate LVM is increased, even in the absence of traditionally defined left ventricular hypertrophy. The increase in aldosterone levels could contribute to the increase of LV mass exceeding the amount needed to compensate hemodynamic load.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18645048     DOI: 10.1161/HYPERTENSIONAHA.108.114140

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  28 in total

1.  Cardiac remodeling in patients with primary aldosteronism.

Authors:  F Galetta; G Bernini; F Franzoni; A Bacca; I Fivizzani; L Tocchini; M Bernini; P Fallahi; A Antonelli; G Santoro
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

2.  Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment.

Authors:  G Bernini; A Bacca; V Carli; D Carrara; G Materazzi; P Berti; P Miccoli; R Pisano; V Tantardini; M Bernini; S Taddei
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

3.  Non-dipper and inappropriate left ventricular mass in hypertensive patients.

Authors:  Sang-Hyun Ihm
Journal:  Korean Circ J       Date:  2011-04-30       Impact factor: 3.243

4.  Potential effects of age on screening for primary aldosteronism.

Authors:  Q Luo; N F Li; X G Yao; D L Zhang; S F Y Abulikemu; G J Chang; K M Zhou; G L Wang; M H Wang; W J Ouyang; Q Y Cheng; Y Jia
Journal:  J Hum Hypertens       Date:  2015-04-16       Impact factor: 3.012

5.  Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new.

Authors:  Cristiana Catena; Gianluca Colussi; Gabriele Brosolo; Lorenzo Iogna-Prat; Leonardo A Sechi
Journal:  Am J Cardiovasc Dis       Date:  2011-12-15

6.  Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism.

Authors:  Qihong Wu; Mona Hong; Jianzhong Xu; Xiaofeng Tang; Limin Zhu; Pingjin Gao; Jiguang Wang
Journal:  Endocrine       Date:  2021-01-21       Impact factor: 3.633

Review 7.  Left heart morphology and function in primary aldosteronism.

Authors:  Alberto Milan; Corrado Magnino; Ambra Fabbri; Michela Chiarlo; Giulia Bruno; Isabel Losano; Franco Veglio
Journal:  High Blood Press Cardiovasc Prev       Date:  2012-03-01

8.  Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage.

Authors:  G Liu; G-S Yin; J-y Tang; D-J Ma; J Ru; X-H Huang
Journal:  J Hum Hypertens       Date:  2014-02-20       Impact factor: 3.012

9.  Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction.

Authors:  Mario Gregori; Giuliano Tocci; Andrea Marra; Giulia Pignatelli; Caterina Santolamazza; Alberto Befani; Giuseppino Massimo Ciavarella; Andrea Ferrucci; Francesco Paneni
Journal:  Clin Res Cardiol       Date:  2013-06-14       Impact factor: 5.460

10.  NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism.

Authors:  Francesca Pizzolo; Francesco Zorzi; Laura Chiecchi; Letizia Consoli; Irene Aprili; Patrizia Guarini; Annalisa Castagna; Gian Luca Salvagno; Chiara Pavan; Oliviero Olivieri
Journal:  Endocrine       Date:  2013-08-13       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.